ABSTRACT
          Background and objectives: Tricyclazole (TCZ) is a member of triazole fungicides, which might cause damage in living systems. This study was carried out to examine effects of TCZ on liver tissues and level of liver enzymes.
            Methods: Forty mice were randomly divided into four groups including control, sham and two experimental groups. Experimental groups 1 and 2 received 5 mg/Kg and 15 mg/Kg intraperitoneal injection of TCZ for two weeks, respectively. The sham group received sterile water but the control group received no injection. The animals were sacrificed 24 h after the last injection, and microscopic slides were prepared for cell counting and evaluation of tissue damage. Levels of liver enzymes were measured using commercial kits. Data was analyzed in SPSS (version 20) using one-way ANOVA.
          Results: The injection of TCZ caused a significant increase in the number of hepatocytes and a significant decrease in the number of Kupffer cells compared to control group (P<0.001). In the experimental group, the level of alanine aminotransferase and aspartate aminotransferase increased, but the level of alkaline phosphatase decreased significantly compared to control group (P<0.001). We also detected several forms of tissue damage including necrosis and degeneration of hepatocytes, hyperplasia, and penetration of inflammatory cells and expansion of sinusoids.
          Conclusion: Our results indicate that the intraperitoneal injection of TCZ in mice can cause irreparable hepatic damage in a dose-dependent manner.
          Keywords: Tricyclazole, hepatocytes, Alanine, Aspartate aminotransferase.

Background: Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. The disease may also affect other parts of the body, including the skin, eyes, lungs, heart, nerves, and blood. This study aimed to evaluate the effect of methotrexate on blood, liver, and renal parameters in patients with RA.
Methods: A six-month cross-sectional study was carried out on 60 consecutive patients aged 19-70 years diagnosed with RA on methotrexate treatment (10 mg) orally per week. A questionnaire was taken from participants, and laboratory tests were done on renal and liver function and complete blood count (CBC), erythrocyte sedimentation rate (ESR), glutamic oxaloacetic transaminase (SGOT or AST), glutamate pyruvate transaminase (SGPT or ALT), Creatinine, C-reactive protein (CRP), and rheumatoid factor (RF) as a follow-up to drug intake.
Results: At the end of sample collection, participants ranged in age from 19 to 70 years, with a female-to-male ratio of 1.5:1. Significant differences in platelet (PLT) levels were observed only between days 1 and 14 of the treatment (p <0.05). Similarly, SGPT levels showed significant variation between days 1 and 30 of the treatment (p <0.05). Additionally, RF levels exhibited significant differences between days 1 and 14 (p <0.01) and between days 1 and 30 of the treatment (p <0.04).
Conclusion: The recommended medication for all kinds of patients with RA is methotrexate, which has had a notable impact on blood, liver, and kidney parameters. These characteristics can serve as indicators for monitoring the medication’s effectiveness, safety, and patient follow-up.